Citing other people interested in the trial, the Daily Telegraph reported last week that the vaccine may be offering a “double defense” opposed to the virus, causing a T-cell reaction and an antibody reaction.The Telegraph also reports that knowledge of the trial will be released on Monday.
CORONAVIRUS VACCINE TRIAL IN THE UK ”PROGRESSING VERY WELL’, RECRUITING OLDER CHILDREN AND ADULTS
Fox News has contacted the University of Oxford and AstraZeneca with a request for comment on this story.
AstraZeneca’s shares rose more than 1% to $61.75 in pre-trading operations.
The Oxford University trial is “progressing very well,” the researchers said in the assignment in May.
AN INVESTIGATIVE VACCINE PROTECTS MONKEYS FROM PNEUMONIACOVID-19
Moreover, in May, UK Secretary of Affairs Alok Sharma said the Oxford vaccine trial, if successful, could deliver 30 million doses until September.The UK government has invested in one hundred million doses of the vaccine, according to reports.
With 296358 instances and 45385 deaths, the United Kingdom is one of the countries most affected by the coronavirus pandemic, according to knowledge compiled through Johns Hopkins University.
Several efforts are underway to expand a coronavirus vaccine worldwide; scientists from the Israeli University of Tel Aviv and biopharmaceutical company Neovii, for example, recently announced an assignment to expand a COVID-19 vaccine.
MORE THAN A HUNDRED YEARS BEFORE CORONAVIRUS, THE SPANISH INFLUENZA PANDEMIC RAVAGED THE WORLD
Experts concerned about the effort say they are the “Achilles heel” of the coronavirus.
As of Monday morning, more than 14.5 million coronavirus cases had been diagnosed worldwide, at least 3.7 million in the United States, according to Johns Hopkins University.
The disease has caused at least 606,206 deaths worldwide, adding up to at least 140534 more people in the United States.
CLICK HERE FOR THE FOX NEWS APP
Christopher Carbone of Fox News contributed to this article.Follow James Rogers on Twitter @jamesjrogers